The Fall and Rise of Essa Pharma
Today’s post highlights the lessons learned as part of the trial and tribulations associated with oncology R&D, including a large dash from vibe of the famous British sitcom, “The Fall and Rise of Reginald Perrin.”
Madrid city centre at dusk
No matter what industry outsiders think, drug development very rarely goes in a straight line from A-Z since there are often many expected – and even unexpected – twists along the way.
The company we’re focusing on is Essa Pharma, and boy, do they have some challenges and unexpected plot twists as part of their corporate DNA!
I often hear from artistic friends paraphrasing Ursula Le Guin that it’s all about the journey, not the destination.
Except in business and especially in Pharmaland, however, it is entirely about the destination and how you get there doesn’t matter so much. After all, if a small biotech doesn’t get a product in development over the finish line (aka approval) and become a commercial success then it’s game over for everyone involved.
This is one of those kind of stories.
A tale of belief, tension, tenacity, re-tooling, and finally, renewed hope…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
